JP Morgan Chase’s DICE Therapeutics DICE Stock Holding History
Bought
Maintained
Sold
JP Morgan Chase's DICE Position: Q3 2023 in Review
JP Morgan Chase sold out of DICE Therapeutics (DICE) in Q3 2023, closing a stake of 618,089 shares — an estimated $28.7M sold.
JP Morgan Chase first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $28.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.
- JP Morgan Chase reported no remaining DICE Therapeutics position as of Q3 2023 after selling out during the quarter.
- JP Morgan Chase sold 618,089 DICE Therapeutics shares in Q3 2023, an estimated $28.7M.
- JP Morgan Chase first reported a position in DICE Therapeutics in Q4 2021 and held it in 7 quarters.
- JP Morgan Chase's DICE Therapeutics position peaked at $28.7M in Q2 2023.
- 0 funds tracked by Wall St. Rank held DICE Therapeutics as of Q3 2023.
Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.